How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Cancer/Tumor Profiling and Pathways Market
- By Technology: Next-Generation Sequencing (NGS), Microarray Analysis, Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH)
- By Application: Genomic Profiling, Transcriptomic Profiling, Proteomic Profiling, Epigenomic Profiling, Metabolomic Profiling
- By Cancer Type: Breast Cancer Profiling, Lung Cancer Profiling, Colorectal Cancer Profiling, Prostate Cancer Profiling, Leukemia and Lymphoma Profiling
- By End User: Hospitals and Cancer Centers, Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes
- By Pathway Analysis Focus: Cell Cycle Regulation Pathways, Apoptosis Pathways, Signal Transduction Pathways, DNA Repair Pathways, Angiogenesis Pathways
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Next-Generation Sequencing (NGS) leads By Technology at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Cancer/Tumor Profiling and Pathways Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Illumina Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Agilent Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →QIAGEN N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →PerkinElmer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →NanoString Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Guardant Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Foundation Medicine (a subsidiary of Roche)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Myriad Genetics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Personalis Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →SomaLogic Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Adaptive Biotechnologies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Freenome
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Next-Generation Sequencing (NGS)31.9
- Microarray Analysis21.0
- Polymerase Chain Reaction (PCR)19.4
- Immunohistochemistry (IHC)15.2
- Fluorescence In Situ Hybridization (FISH)12.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific15.8
- Illumina Inc.13.7
- Agilent Technologies9.9
- QIAGEN N.V.9.9
- Roche Diagnostics7.9
- Bio-Rad Laboratories14.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.4
- Europe22.9
- Asia Pacific19.4
- Latin America14.1
- Middle East and Africa9.1
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 82 | 75 | 88 | 99 | 75 | 96 | 86 |
| Illumina Inc. | 77 | 70 | 69 | 93 | 70 | 90 | 78 |
| Agilent Technologies | 75 | 66 | 85 | 78 | 82 | 80 | 78 |
| QIAGEN N.V. | 81 | 65 | 76 | 68 | 59 | 65 | 69 |
| Roche Diagnostics | 61 | 75 | 68 | 69 | 58 | 68 | 67 |
| Bio-Rad Laboratories | 59 | 52 | 53 | 54 | 69 | 62 | 58 |
| PerkinElmer Inc. | 46 | 66 | 65 | 44 | 57 | 58 | 56 |
| NanoString Technologies | 42 | 36 | 59 | 56 | 39 | 57 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Illumina Inc.
- Agilent Technologies
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Illumina Inc. | ✓ | − | ✓ | ✓ | ◐ | ◐ |
| Agilent Technologies | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| QIAGEN N.V. | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Roche Diagnostics | − | ◐ | ✓ | ◐ | ◐ | ◐ |
| Bio-Rad Laboratories | ◐ | − | − | ◐ | ◐ | ◐ |
| PerkinElmer Inc. | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| NanoString Technologies | − | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Technology in North America, then scale across Cancer/Tumor Profiling and Pathways Market — a $525M beachhead inside a $7.77B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Next-Generation Sequencing (NGS)
Best fit — highest urgency & budget in Technology.
Microarray Analysis
Strong fit — clear ROI and a fast path to value.
Polymerase Chain Reaction (PCR)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Technology in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Cancer Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Technology leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cancer/Tumor Profiling and Pathways Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Cancer/Tumor Profiling and Pathways Market is a durable-growth opportunity — $1.64B by 2033, compounding at 9.6%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.6% CAGR
Demand compounds through 2033, outpacing GDP across Technology.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Technology moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Cancer/Tumor Profiling and Pathways Market — a $5.92B market by 2033. Plan: grow share from 7.0% to 15.0%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.0% | 15.0% | Ahead |
| Revenue | $425M | $887M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 32.2% | 44.7% | Ahead |
| Customer retention | 90.9% | 93.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Technology
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Technology share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $117M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Technology leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentAt risk
Sales deck · value proposition
Win the Cancer/Tumor Profiling and Pathways Market conversation — a $1.27B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Technology
Goal Grow share in Technology
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cancer/Tumor Profiling and Pathways Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Cancer/Tumor Profiling and Pathways Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Cancer Tissue Diagnostics Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportCancer Therapy and Testing Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportCancer Therapies Market
Market size, share, segmentation and regional forecast.
$952M market · 2025 base year
View reportCancer Therapeutics And Biotherapeutics Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportCancer Test Kits Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportCancer Testing Kits Market
Market size, share, segmentation and regional forecast.
$999M market · 2025 base year
View reportCancer Targeted Small Molecule Therapy Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportCancer Targeted Drug Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportCancer Stem Cell Therapy Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportCancer Spit Test Device Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportCancers Immunotherapy Drugs Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportCancer Screening Tests Market
Market size, share, segmentation and regional forecast.
$447M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy